Is inhaled insulin delivery still a possibility? Why has it been a commercial failure?

New Rochelle, NY, September 23, 2009 -- The commercial failure of Exubera® (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market. Does this signal defeat for efforts to deliver insulin via the lungs?

Read the whole article on Science Blog

More from Science Blog